Rotinen Díaz, Mirja Sofia

Profile Picture

Email Address

person.page.identifierURI

https://academica-e.unavarra.es/handle/2454/49902

Birth Date

Job Title

Last Name

Rotinen Díaz

First Name

Mirja Sofia

person.page.departamento

Ciencias de la Salud

person.page.instituteName

IMAB. Research Institute for Multidisciplinary Applied Biology

ORCID

0000-0002-0755-8360

person.page.observainves

750895

person.page.upna

7847

Name

Filters

2023 - 20242
Reset filters

Settings

Start date: 2020 × Subject: Targeted therapy ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationUnknown
    Actionable driver events in small cell lung cancer
    (MDPI, 2024) Gutiérrez Núñez, Mirian; Zamora Álvarez, Irene; Freeman, Michael R.; Encío Martínez, Ignacio; Rotinen Díaz, Mirja Sofia; Ciencias de la Salud; Osasun Zientziak
    Small cell lung cancer (SCLC) stands out as the most aggressive form of lung cancer, characterized by an extremely high proliferation rate and a very poor prognosis, with a 5-year survival rate that falls below 7%. Approximately two-thirds of patients receive their diagnosis when the disease has already reached a metastatic or extensive stage, leaving chemotherapy as the remaining first-line treatment option. Other than the recent advances in immunotherapy, which have shown moderate results, SCLC patients cannot yet benefit from any approved targeted therapy, meaning that this cancer remains treated as a uniform entity, disregarding intra- or inter-tumoral heterogeneity. Continuous efforts and technological improvements have enabled the identification of new potential targets that could be used to implement novel therapeutic strategies. In this review, we provide an overview of the most recent approaches for SCLC treatment, providing an extensive compilation of the targeted therapies that are currently under clinical evaluation and inhibitor molecules with promising results in vitro and in vivo.
  • Thumbnail Image
    PublicationUnknown
    Targeting key players of neuroendocrine differentiation in prostate cancer
    (MDPI, 2023) Zamora Álvarez, Irene; Freeman, Michael R.; Encío Martínez, Ignacio; Rotinen Díaz, Mirja Sofia; Ciencias de la Salud; Osasun Zientziak
    Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer (PC) that commonly emerges through a transdifferentiation process from prostate adenocarcinoma and evades conventional therapies. Extensive molecular research has revealed factors that drive lineage plasticity, uncovering novel therapeutic targets to be explored. A diverse array of targeting agents is currently under evaluation in pre-clinical and clinical studies with promising results in suppressing or reversing the neuroendocrine phenotype and inhibiting tumor growth and metastasis. This new knowledge has the potential to contribute to the development of novel therapeutic approaches that may enhance the clinical management and prognosis of this lethal disease. In the present review, we discuss molecular players involved in the neuroendocrine phenotype, and we explore therapeutic strategies that are currently under investigation for NEPC.